Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why
01:01pm, Monday, 25'th Nov 2024
Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Allogene Therapeutics Announces Participation in December Investor Conferences
08:30am, Tuesday, 19'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene's Q3 Loss Narrower Than Expected, Sales Nil
11:15am, Friday, 08'th Nov 2024
ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter.
Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript
08:59pm, Thursday, 07'th Nov 2024
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants Christine Cassiano - Chief Corporate Affair and Brand Strategy Officer David
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
04:02pm, Thursday, 07'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting
09:10am, Tuesday, 05'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know
11:06am, Thursday, 31'st Oct 2024
Allogene Therapeutics (ALLO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
08:30am, Wednesday, 30'th Oct 2024
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity
04:11pm, Wednesday, 02'nd Oct 2024
Allogene Therapeutics, Inc. (ALLO, Financial) saw a significant drop in its stock price, falling 5.06% to $2.54 per share. The trading volume reached 1.41 million shares, with a turnover rate of 0.67%
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
11:47am, Monday, 30'th Sep 2024
Positive interim results released from phase 1/1b study using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory Multiple Myeloma. The global multiple myeloma market is projected to r
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
08:30am, Monday, 30'th Sep 2024
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
SAN JOSE, Calif.--(BUSINESS WIRE)---- $CALX #calix--Today, Calix, Inc. (NYSE: CALX) reaffirmed the power of its cloud-and-software broadband platform to enable customers to simplify their business, in
FDA evaluated RMAT application based on positive clinical data from ongoing Phase 1 study of P-BCMA-ALLO1; new clinical data from the study will be presented at the 21st International Myeloma Society
